SCHEMBL30765609

SCHEMBL30765609

O=C(O)Cn1c(-c2ccccc2)cnc(NCc2ccc(Oc3ccccc3)cc2)c1=O

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
F2 P00734 3/20 0.51
F7 P08709 3/20 0.51
F3 P13726 3/20 0.51
FFAR1 O14842 4/20 0.46
FFAR4 Q5NUL3 2/20 0.46
GAA P10253 2/20 0.46
AURKA O14965 1/20 0.45
RPS6KB1 P23443 1/20 0.45
KMT2A Q03164 1/20 0.43
KDM4C Q9H3R0 1/20 0.43
FLT1 P17948 1/20 0.41
KDR P35968 1/20 0.41
FYN P06241 1/20 0.39
BACE1 P56817 1/20 0.39
GNA15 P30679 1/20 0.39
PTGER3 P43115 1/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765959 0.91 F2 (0.49) F2F7F3FFAR1FFAR4
SCHEMBL30765483 0.90 F2 (0.55) F2F7F3FFAR1FFAR4
SCHEMBL23460811 0.90 F2 (0.56) F2F7F3GAAKMT2A
SCHEMBL23460662 0.87 F2 (0.52) F2F7F3GAAKMT2A
SCHEMBL30765940 0.82 KMT2A (0.52) F2F7F3GAAKMT2A
SCHEMBL23460748 0.81 F2 (0.53) F2F7F3GAAKMT2A
SCHEMBL23474324 0.81 F2 (0.60) F2F7F3GAAAURKA
SCHEMBL30765786 0.79 F2 (0.48) F2F7F3KDM4C
SCHEMBL30765992 0.79 MAPT (0.52) GAAKMT2AKDM4CTDP1
SCHEMBL23461145 0.79 F2 (0.65) F2F7F3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed